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Jennifer Marie Theresia Anna Meessen11, Rustam Al-Shahi Salman13, Elisabetta Dejana10, Roberto Latini11 and the
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Abstract
Background: Cerebral cavernous malformations (CCMs) are vascular malformations characterized by clusters of
enlarged leaky capillaries in the central nervous system. They may result in intracranial haemorrhage, epileptic
seizure(s), or focal neurological deficits, and potentially lead to severe disability. Globally, CCMs represent the
second most common intracranial vascular malformation in humans, and their familial form (FCCMs) accounts for
one-fifth of cases. Neurosurgical excision, and perhaps stereotactic radiosurgery, is the only available therapeutic
option. Case reports suggest that propranolol might modify disease progression.
Methods: Treat_CCM is a prospective, randomized, open-label, blinded endpoint (PROBE), parallel-group trial
involving six Italian clinical centres with central reading of brain magnetic resonance imaging (MRI) and adverse
events. Patients with symptomatic FCCMs are randomized (2:1 ratio) either to propranolol (40–80 mg twice daily) in
addition to standard care or to standard care alone (i.e. anti-epileptic drugs or headache treatments). The primary
outcome is intracranial haemorrhage or focal neurological deficit attributable to CCMs. The secondary outcomes are
MRI changes over time (i.e. de novo CCM lesions, CCM size and signal characteristics, iron deposition, and vascular
leakage as assessed by quantitative susceptibility mapping and dynamic contrast enhanced permeability), disability,
health-related quality of life, depression severity, and anxiety (SF-36, BDI-II, State-Trait Anxiety Inventory).
Discussion: Treat_CCM will evaluate the safety and efficacy of propranolol for CCMs following promising case
reports in a randomized controlled trial. The direction of effect on the primary outcome and the consistency of
effects on the secondary outcomes (even if none of them yield statistically significant differences) of this external
pilot study may lead to a larger sample size in a definitive phase 2 trial.
Trial registration: ClinicalTrails.gov, NCT03589014. Retrospectively registered on 17 July 2018.
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Background and rationale
Cerebral cavernous malformations (CCMs) are vascular
lesions consisting of clusters of abnormally dilated blood
vessels (capillaries). These lesions are mainly located in
the central nervous system (brain and spinal cord) and,
more rarely, affect the skin and retina. CCMs have typ-
ical raspberry-like appearance due to their composition
of multiple bubble-like structures called caverns. Each
cavern is filled with blood and lined by a layer of endo-
thelial cells. In the case of CCMs, the bubble-like cav-
erns are grossly dilated vessels that leak due to defects in
the endothelial cells and due to the loss of other struc-
tural components that are required for vessel wall integ-
rity. Lesion size is variable, ranging from microscopic to
a few inches in diameter. Subjects may be asymptomatic
or present a wide variety of symptoms including sei-
zures, intracranial haemorrhages, or focal neurological
deficits [1–3].
The CCM prevalence is approximately one out of
every 500–600 people. However, such an estimation
strongly depends on the methodology of ascertainment.
Autopsy studies indicate the prevalence of CCMs to be
between 0.2% and 0.5% of the population, while papers
using brain MRI clinical series report a prevalence be-
tween 0.39% and 0.9% [4–6].
CCMs occur in sporadic or familial (FCCM) forms.
Multiple lesions are more common in FCCMs and the
number of lesions is strongly correlated with the pa-
tient’s age. The diagnosis of FCCMs is established with
the presence of either or both of the following: multiple
CCMs, and multiple family members with one or more
CCM. The identification of a heterozygous germline,
pathogenic variant in KRIT1, CCM2, or PDCD10 con-
firms the diagnosis of FCCMs [7]. Genetic screening is
positive in 96% of families with multiple affected mem-
bers, and in 57% of sporadic cases with multiple lesions
(more so if new lesions form over time) [2]. While
FCCM patients bear ubiquitous germline heterozygous
mutation of CCM genes, the analysis of the surgically re-
moved cavernomas discloses a second somatic mutation
in the same CCM gene. This suggests that local genetic
homozygosity is indispensable to prime the pathogenic
cascade. The analysis of affected tissues often discloses a
second somatic mutation, which is likely indispensable
to prime the pathogenetic cascade, suggesting a two-hit
mechanism [8–10]. The prevalence of FCCMs, highly
variable among different populations and case series,
ranges from 0.2 to 3/10,000 subjects [11, 12]. Multiple
CCMs, suggesting FCCMs, affect roughly one-fifth of
people with CCMs [1]. Nonetheless, these new findings
on genetic determinants have not impacted on actual
treatment of CCMs.
Although the presentation of CCMs is not uncommon
in children, individuals often show the first sign of
symptoms in their 20s or 30s. Globally, the annual
bleeding rate is 2.5% per patient-year, with prior haem-
orrhage and brain stem location being the major risk
factors for CCMs to bleed [1, 13].
CCM is an endothelial disease as demonstrated in
murine models. In fact, only mice with endothelial-
selective inducible ablation of FCCM genes develop
cerebral vascular malformations with morphological and
molecular features similar to humans [14–16]. The activ-
ity of the three members of the complex, encoded by the
three FCCM-related genes, has to converge in the same
pathway, since the morphology and specific brain
localization of the vascular malformations is roughly
comparable in the three genetic forms of FCCM.
No pharmacological treatment is at present available
to inhibit the formation of new malformations, to
stabilize the existing ones and stop their progression. To
date, the standard of care is represented by treatment of
CCM-associated clinical manifestations, such as head-
ache and epilepsy, and consists of anti-epileptic drugs or
drugs for recurrent headache [17]. The only available
treatments are neurosurgical excision or stereotactic ra-
diosurgery. Surgical removal of lesions associated with
intractable seizures or focal deficits from recurrent
haemorrhage or mass effect may be considered [13, 18,
19], with at times significant complications [20]. Neither
neurosurgery nor radiosurgery can completely eradicate
the multiple lesions of FCCMs, which increase in num-
ber over time. Thus, pharmacological therapies are ur-
gently needed, particularly in FCCMs.
Propranolol has efficacy, documented in RCTs, for the
treatment of infantile haemangiomas, another common
vascular lesion affecting the skin [21–24]. To date, only
anecdotal reports have been published supporting its ef-
ficacy in CCMs [19, 25–27]. In mice, propranolol was ef-
fective in preventing CCM expansion and in reducing
vascular permeability (Matteo Malinverno et al., 2019,
unpublished data).
The recognized safety of propranolol, as demonstrated
by millions of patients of all ages, including children
treated over the last 40 years [28], makes this drug a




The purpose of this exploratory pilot trial is to test
whether 2-year treatment with propranolol in addition
to standard care can reduce the incidence of clinical
events, as compared to standard care in patients with
FCCMs. Furthermore, this trial will help to set up future
clinical trials in an area where there is to date no ap-
proved drug reducing the progression of CCM lesions,
and will pave the way to study the mechanisms
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underlying the possible therapeutic role of propranolol
in CCMs.
Design
The study protocol was designed according to the real-
life management of patients with FCCMs (Fig. 1). Treat_
CCM is a multicentre, open-label, randomized con-
trolled trial (PROBE design, prospective randomized
open trial with blinded evaluation of outcomes) in pa-
tients with FCCMs. Patients, fully informed of the trial,
after signing the informed consent form are randomly
assigned by computer, upon completing the
randomization electronic case report form (e-CRF), in a
2:1 ratio to the study groups: one receiving propranolol
in addition to standard care; the other, controls, receiv-
ing standard care alone (Fig. 1). The study will be open-
label since the implementation of blinding would require
placebo and ad hoc procedures with costs non-
sustainable in a pilot study fully supported by public
funding. In order to reduce possible biases, a PROBE de-
sign will be applied so that each MRI examination will
be centrally read after de-identification, and all adverse
clinical events will be centrally adjudicated. It should be
pointed out that by no means will surgery, whenever in-
dicated, be delayed and/or avoided because of study
treatment allocation.
A two-step trial [29] is proposed as follows:
 Step 1: duration 2 years; 60 patients, 40 in
propranolol group and 20 controls; if no difference
between the study groups in 2-year incidence of ad-
verse clinical events (e.g. intracerebral haemorrhage
(ICH) or focal neurological deficits (FND)) is found
and different MRI variables suggest improvement,
the second phase is started, to assess long-term effi-
cacy of propranolol.
 Step 2: single-arm study, all patients in the propran-
olol group; the drug will be declared effective in the
case that the patients’ condition is improved or re-
mains stable over the 2-year follow-up (e.g. years 3
and 4). The threshold of proportion of responses will
be defined upon analysis of the 2-year follow-up
data.
Population
Eligible patients will be selected from the six participat-
ing clinical centres (Fondazione IRCCS Cà Granda
Ospedale Maggiore Policlinico, Milan; Policlinico Uni-
versitario Agostino Gemelli, Rome; Fondazione IRCCS
Istituto Neurologico Carlo Besta, Milan; Fondazione
IRCCS Casa Sollievo della Sofferenza, San Giovanni
Rotondo; IRCCS Centro Neurolesi “Bonino Pulejo”,
Messina; ASST Grande Ospedale Metropolitano
Niguarda Milan). In addition, other patients will be iden-
tified via CCM patient organizations, such as Associa-
zione Nazionale Angioma Cavernoso Cerebrale ONLUS
(https://www.anacc.net/). Inclusion and exclusion cri-
teria are listed in Table 1.
Intervention
Propranolol is a non-selective beta-blocker, indicated for
the treatment of hypertension and other cardiovascular
and neurological disorders. The recommended initial
oral dose for the group randomized to propranolol is 40
Fig. 1 Study flow chart. bid twice daily, CCM cerebral cavernous malformation
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mg twice daily, as recommended in Italian Pharmaco-
peia, to be up-titrated to 80 mg twice daily in the ab-
sence of excessive bradycardia (e.g. heart rate < 50 bpm)
or hypotension. However, doses as low as 10mg twice
daily and up to 160 mg twice daily, 20–320 mg daily, are
acceptable according to the individual’s tolerance of side
effects. Both study groups will receive recommended
standard care. Study treatment will be continued for the
whole duration of the study.
Outcomes
The primary endpoint will be the new occurrence of
clinical symptomatic CCM-related events, which are in-
tracerebral haemorrhage (ICH) and focal neurological
deficits (FND), as defined by Al-Shahi Salman et al. [30],
excluding seizures.
Secondary endpoints include the following:
1. Microvascular haemorrhages as assessed by MRI
analysis of brain tissue magnetic susceptibility, a
biophysical property proportional to the local iron
content (susceptibility weighted imaging (SWI) and
quantitative susceptibility mapping (QSM)), and
dynamic contrast enhanced permeability (DCEP).
2. Clinical outcomes, other than ICH and FND, such
as global disability, health-related quality of life, de-
pression severity, and two types of anxiety (state
anxiety, or anxiety about an event, and trait anxiety,
or anxiety personal level), as assessed by the SF-36,
BDI-II and State-Trait Anxiety Inventory (STAI)
questionnaires.
3. Seizures.
4. Different MRI CCM characteristics, such as
location (cerebellum, brainstem, right/left
hemispheric white matter, right/left basal ganglia),
diameter, length, and MRI signal appearance.
Lesions with previous surgical treatment will be
excluded from imaging analysis.
5. Appearance of de novo CCM lesions at MRI.
Exploratory targets
Brain imaging
MRI is, at present, the objective non-invasive tool to
track in vivo the evolution of CCMs. Recently, in vivo
MRI assessment of iron deposition and vascular perme-
ability with advanced MRI techniques, such as QSM and
DCEP, have been proposed as objective and quantifiable
biomarkers of disease activity in CCMs with potential
application in natural history and clinical trials [31],
expanding conventional imaging in cerebral cavernous
malformations [32]. Iron leakage and vascular perme-
ability have a central role in CCM pathogenesis and
their quantification can be an objective biomarker of dis-
ease activity in CCMs. Therefore, the quantification of
biomarkers of DCEP and QSM with in vivo MRI and
their longitudinal changes may correlate with the clinical
behaviour of CCMs [33]. Patients will undergo brain
MRI at randomization and at 1 and 2 years of follow-up.
Biobanking/biomarker study
The identification of circulating biomarkers in a popula-
tion of CCM patients with recorded clinical history and
documented therapeutic response will potentially con-
tribute to establish prognostic and response-to-therapy
indicators in the peripheral blood of CCM patients. Bio-
markers to monitor CCM are urgently needed and are
potentially fruitful according to several reports on other
cerebrovascular disorders [34]. Indeed, specific circulat-
ing miRNAs have been reported in infantile haemangi-
omas which respond to propranolol [35], in cerebral
aneurisms [36], and for cerebral haemorrhagic and is-
chaemic stroke [37]. Patients will undergo blood sam-
pling for biobanking at randomization, at 1 month, and
at 1 and 2 years of follow-up.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1 Patients with familial cerebral cavernous malformations (FCCM)
2 History of clinical symptoms or events: ICH, seizures, stroke,
permanent or transient focal deficits, intellectual disability, or any
other neurological symptoms supposedly related to CCM
3 Age ≥18 years
4 Written informed consent to participate in the study prior to any
study procedures
Exclusion criteria
1 Implanted pacemaker or any other condition preventing the MRI
examination




5 Liver and/or renal failure
6 Current use of verapamil or diltiazem for risk of excessive
bradycardia
7 Previous brain surgery (within 6 months)
8 Known hypersensitivity to study drug (propranolol or any of the
ingredients)
9 Pregnant or lactating women, or women at risk of childbearing
who are not under protection by an accepted method of
contraception
10
Participation to another clinical trial
11
Inability to cooperate with the trial procedures
In addition to these specific exclusion criteria, all well-documented
contraindications to beta-blocker use are also valid in this trial
AV atrioventricular, CCM cerebral cavernous malformation, ICH intracerebral
haemorrhage, MRI magnetic resonance imaging
Lanfranconi et al. Trials          (2020) 21:401 Page 4 of 10
Microbiome
In a murine model of FCCMs, it has been reported that
the microbiome composition influences the progression
of brain angiomas [38]. Recent data in 75 patients go
along the same line [39] and therefore it is of interest to
characterize patients included in Treat_CCM at baseline
as well as during disease evolution. Stools will be sam-
pled for microbiome analysis at randomization, at 1
month, and at 1 and 2 years of follow-up.
Follow-up phase
Follow-up clinical visits will be performed at weeks 2
and 4 for dose adjustment of the study medication plus
adverse events and side effect monitoring, and then
every 6months until the study end at month 24. Visits
at 12 and 24 months are mandatory for MRI, and blood
and faeces sampling for biobanking. Six-month and 18-
month visits can be substituted with a telephone inter-
view by a member of clinical study site staff to check for
her/his vital status and whether any serious adverse
event has occurred (Fig. 2).
Sample size
To the best of the available knowledge, the 2-year risk of
CCM-related events (ICH and FND) was estimated at
10.1% in CCM patients receiving recommended standard
care [1]. Upon performing a formal sample size
calculation, 834 patients should be included in the study
to demonstrate a risk reduction of 50% with a power of
80% at a significance level of one-tailed α = 0.05. This es-
timate is unrealistic both for the over-optimistic treat-
ment effect size and for the number of patients to be
included, incompatible with a rare disease.
Therefore, in order to obtain preliminary data, a pilot
study is planned, adopting a confidence interval ap-
proach, rather than using the more usual power and
statistical significance method [40]. The sample size cal-
culation for the pilot trial is driven by the proposed sam-
ple size of the main trial. According to the nature of the
pilot study design, an 80% one-sided confidence interval
is chosen, instead of the 95% two-sided interval usually
considered for formal comparative trials. With 60 pa-
tients randomized in a 2:1 propranolol:control ratio, in
the absence of a reduction of adverse events, a clinically
meaningful effect, defined as ≥50% reduction of the 2-
year risk of CCM-related events, can be excluded by the
defined 80% upper confidence interval. Otherwise, the
study will provide a promising signal of activity.
Modality of data processing
The data and the samples collected for the study will be
processed as coded data. The treating physician will
identify each patient within the study with a code. This
code will not enable direct identification, unless at the
STUDY PERIOD 
soPnoitacollAtnemlornE tuo-esolCnoitacolla-t
TIMEPOINT -t1 0 Week 2 Week 4 Month6 Month 12 Month 18 Month 24 tx
ENROLMENT: 
Eligibility screen X        31 July 2019
Informed consent  X        31 July 2019
Allocation  X       31 July 2019
INTERVENTIONS: 
Study treatment delivery  X   X X X  31 Jan 2021
ASSESSMENTS: 
Clinical visit  X X X  X  X 31 July 2021
ECG  X X X  X  X 31 July 2021
Collection of blood samples  X  X  X  X 31 July 2021
Collection of stool sample  X  X  X  X 31 July 2021
Brain Magnetic Resonance Imaging  X    X  X 31 July 2021
SAE and AE records 31 July 2021
Fig. 2 Study plan and timeline according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement
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clinical centre where this code will be securely stored to-
gether with the patient’s name and surname. For bio-
logical analyses, researchers will identify samples and the
data connected to them only through this code. No asso-
ciation between the results of scientific investigations on
the samples and the patient’s identity will be possible.
De-identified biological samples will be stored, under
UNI EN ISO 9001: 2015 regulations (for the following:
collection, storage, and distribution of biological samples
and related data for scientific research), transferred, and
processed with modalities that guarantee their quality,
integrity, availability, and traceability. All of the mea-
sures for the correct storage and handling will be put in
place, according to the study protocol.
Only the treating physician, the monitors, and the
regulatory authorities will have access to patient’s data at
the clinical centre and will be able to associate the code
with patient’s name for verification purposes. In particu-
lar situations, and only after the authorization of the
clinical centre and of the promotor, Istituto di Ricerche
Farmacologiche Mario Negri, its delegates may also have
access to identifiable data.
Quality control and trial monitoring
The safety profile of propranolol is reassuring and is
documented by millions of patients of all ages, including
infants treated mostly, but not only, for cardiovascular
disorders over the last 40 years. Despite the expected
very low probability of adverse effects related to pro-
pranolol, patients shall be controlled in particular for
heart rate, blood pressure, and other adverse reactions
possibly attributable to propranolol.
Quality control activities will be applied by the Study
Secretariat at IRCCS-Mario Negri (IRFMN) to each
stage of data handling to ensure data are recorded and
reported in compliance with the protocol. All of the
electronic case report forms (e-CRFs) will be reviewed
for completeness and accuracy at the Study Secretariat
by trained staff; errors and omissions will be entered on
data query forms returned to the investigator for reso-
lution. The Data Safety and Monitoring Board (DSMB)
will monitor the safety data in the project in an ongoing
basis. Serious and non-serious adverse events (SAEs and
AEs) that coincide with primary and secondary end-
points will be collected on the e-CRFs and evaluated by
the DSMB. Investigators shall report to the Study Secre-
tariat (IRFMN) all SAEs suspected to be related to the
study medications or any serious adverse drug reaction
(SADR) within 24 h of learning of its occurrence.
On-site monitoring visits will be performed at site
opening and at regular intervals throughout the study.
On average, four on-site monitoring visits are foreseen
for each participating site. During the visit, a certified
monitor will verify adherence to the protocol:
completeness, accuracy, and consistency of the data; and
adherence to Good Clinical Practice (GCP) and local
regulations on the conduct of clinical research. The in-
vestigator should guarantee access to source documents
for the monitor. The clinical monitor will check partici-
pant medical records and other trial-related records
(source documents) to verify the data reported to the
sponsor on the e-CRFs and in all required reports. The
clinical monitor will communicate deviations from the
protocol to the investigators and will ensure that appro-
priate action designed to prevent recurrence of the de-
tected deviations is taken and documented. Deviations
from study protocol will be entered into the Protocol
Deviation Log and communicated to the sponsor. All of
the monitoring activities will be documented according
to GCP rules and reported to the sponsor.
Study committees
In order to assess primary and secondary endpoints of
this open trial, a PROBE design will be adopted. The fol-
lowing procedures will be implemented:
 Clearly defined objective outcomes: the primary
outcome events of the study are based on objective
clinical assessment, and the imaging secondary
endpoint will be calculated from MRI examinations
read in a central laboratory by experienced neuro-
radiologists, unaware of patient identification and
study treatment.
 Blinded Endpoint Adjudication Committee: all
outcome events will be adjudicated by blinded
adjudication experts. Blinding of all event
documentation will be performed by trained
personnel at the Study Secretariat. The role of the
independent Clinical Event Committee will be to
oversee the blinded adjudication of all primary
events. This Committee will report to the Steering
Committee. Records of all adjudication decisions
and of Clinical Event Committee minutes will be
maintained.
 Data handling: at the Study Secretariat,
identification of treatment allocation on the e-CRF
will only occur where necessary in order to
minimize access to treatment information during
data handling.
 Steering Committee: the Steering Committee will
include one representative for each participating
clinical centre, the Principal Investigator (ED, IFOM,
sponsor of the trial), one representative of the
Patient’s Association, and a representative
responsible for the Study Secretariat and has the full
responsibility for the planning, conduction, analysis,
publication of the study protocol, and results.
Lanfranconi et al. Trials          (2020) 21:401 Page 6 of 10
 Clinical Event Committee (CEC): CEC members will
be independent and will not have direct contact
with patients randomized into this trial. The main
roles and responsibilities of the CEC are: to agree on
definitions of the clinical endpoints and on standard
procedures for assessing these endpoints, and to
validate blindly the events recorded and reported by
the Investigators as endpoints of the study. A
Clinical Event Committee manual will be prepared
and approved by the members of the CEC.
 Data and Safety Monitoring Board (DSMB): the
roles and responsibilities of the Data and Safety
Monitoring Board (DSMB) will be defined by the
same DSMB with special focus on intensive
monitoring of the safety aspects in the whole study
population. Safety reports will be made available to
the DSMB by the study statistician every 6 months.
No specific interim analysis is foreseen for efficacy,
unless required by the Steering Committee or
DSMB because of safety concern.
Centralized laboratories
 MRI Core Laboratory (Policlinico MI):
examinations will be sent as digital recordings to
the MRI Core Laboratory, where a central
reading will be performed. A users’ manual for
MRI will be made available to the participating
centres to ensure common standard methods of
image acquisition.
 Biobank (IRFMN): the coordination of the
collection, long-term storage of biological samples
in a centralized UNI EN ISO 9001: 2015-certified
(for the following: collection, storage, and distri-
bution of biological samples and related data for
scientific research) biobank, and distribution of
de-identified biological samples. In particular,
blood samples will be collected from patients at
the time of MRI (randomization, 12 months, and
24 months) and at the 4-week visit.
 Circulating biomarker assays laboratory (IFOM):
serum/plasma samples from patients before the
beginning of the treatment will be used to
characterize the circulating miRNAs and identify a
CCM patient-specific miRNA signature in compari-
son to age-matched and sex-matched healthy indi-
viduals. In addition, we will test the power of the
miRNA signature to monitor the response to the
pharmacological treatment with propranolol and the
progression of the disease [35, 41].
 Microbioma will be assessed by the 16S technique in
stool samples collected at randomization, 12
months, and 24 months [38].
Guidelines for stopping treatment
A permanent discontinuation of trial medication should
be considered only when one of the following conditions
exists:
 A patient decides that it is in her/his best interest to
withdraw her/his consent to continue study
treatment
 A serious adverse event occurs that is suspected to
be related to trial medication and/or prevents
patient’s continuation on study medication
 An investigator considers it advisable for sound,
explicit, and documented clinical reasons
In all of these cases, the scheduled follow-up visits will
be continued as planned by the study protocol. A patient
will be considered discontinued from the study only if
he or she withdraws their consent to be followed by the
participating centre, or he or she is lost to follow-up
after exhausting all means of contact. Surgical correction
of CCM during follow-up shall require the patient’s dis-
continuation from the study.
In the case of discontinuation, the status of the patient
at the last visit or last available contact will be used for
the final analysis. Vital status may be ascertained
through public records, in the case of failure of all other
methods of contact.
Statistical analyses
The main analysis will be performed according to an
intention-to-treat (ITT) approach. Therefore, all patients
randomized in the study will be included in the analysis.
As we cannot conduct inferential statistics on the data
collected in the pilot study, we will only compare the
proportions of adverse events between the groups to as-
sess the safety of propranolol [42]. A per-protocol ana-
lysis is foreseen.
Baseline characteristics will be presented by treatment
groups, and descriptive statistics will be performed to as-
sess the success of randomization. Kaplan–Meier curves
will be constructed to illustrate the occurrence of ad-
verse events in the study over time.
Concerning the analysis of this pilot study, we are only
interested in whether the treatment estimate is larger or
smaller than zero. Consequently, it is not necessary to for-
mally undertake a hypothesis test of the results. An exten-
sion of the trial in the case of encouraging preliminary
results is foreseen. Special care will be paid to the biologic
consistency of the different endpoints, even if none of
them will yield statistically significant differences.
Discussion
To the best of our knowledge, from a search of Clinical-
Trials.gov on 29 April 2019, at present only one
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interventional trial with long-term drug treatment of
CCMs is registered, testing atorvastatin in 80 patients
with CCMs (AT CASH EPOC; NCT02603328). This
single-centre trial is double-blinded vs placebo, with 1:1
randomization [43].
Considering the lack of effective pharmacological
treatments of CCMs, and the safety and wide availability
of propranolol, there is a risk that this drug will be pre-
scribed off-label also in the absence of clear evidence of
benefit. Therefore, it is imperative to maximize inclusion
and perform randomized trials as soon as possible.
Some limitations are to be acknowledged. Firstly, the
non-blind design may cause biases in the reporting of
subjective variables such as quality of life; however, the
PROBE design should protect from major influences on
endpoint variables. Secondly, the number of patients to
be enrolled is suitable for a pilot trial, which may at best
reassure the safety of the study drug in patients with
CCMs and provide the rationale for a future adequately
sized trial, difficult in view of the low prevalence of
CCMs and possible non-evidence-based preferences for
treatments [44].
Treat_CCM aims at triggering effective transnational
collaboration in order to assess the efficacy of propran-
olol in FCCMs by extending access to the trial also to
children. The efficacy of propranolol in the much more
frequent sporadic form of the disease could also be
tested. Moreover, in the case of encouraging results, as
judged by the Steering Committee, a larger phase 2,
single-arm trial may be started.
Trial status
The first patient was included in Treat_CCM in March
2018, and, as of the end of April 2019, 57 patients have
been included. Recruitment is ongoing and, according to
the study protocol, each patient will be followed up for
at least 2 years. The current protocol is version 2.5 cre-
ated on 30 November 2018. Any protocol modifications
will be communicated to relevant parties (e.g. trial
participants) and published on relevant channels (e.g.
Clinicaltrials.gov). The results of this trial will be pub-
lished in an appropriate scientific journal.
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